 |
|
Portal vein thrombosis is common in extraportal vein obstruction
October 15, 2007Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed. Cirrhosis and tumor related portal vein thrombosis patients are older and have grim prognoses. Hypercoagulable state as a cause of portal vein thrombosis is less common. The idiopathic group comprises the second largest number of patients.
A research article to be published on October 21 in the World Journal of Gastroenterology addresses the etiology and clinical outcome of portal vein thrombosis. The research team led by Dr. Pankaj Jain and Dr. Sandeep Nijhawan from Sawai Man Singh Hospital, Jaipur worked on patients with portal vein thrombosis for two years. The researchers had observed that patients with portal vein thrombosis in the two groups behaved differently in etiology, presentation and prognosis. Therefore, they collected data from their centre to verify the differences.
The researchers included cirrhosis and tumor-related AND non-cirrhotic non-tumoral extrahepatic portal venous obstruction. The large sample size allowed them to obtain significant results and draw very reliable conclusions.
Factor V Leiden mutation was present in 2% of cases and is uncommon in India. Umbilical sepsis in childhood or catheterization of umbilical veins in the neonatal period may be responsible for extrahepatic portal vein obstruction in the developing countries.
Extrahepatic portal vein obstruction (EHPVO) patients were young and commonly presented with features of hematemesis, hypersplenism, pain abdomen and abdominal distension. Ten patients had acute PVT and two had presentation as acute Budd-Chiari syndrome. Cirrhosis and tumor-related portal vein thrombosis presented with abdominal distension, abdominal pain and jaundice. On follow-up of a mean period of 7 months (range 1-24 months), 48% patients had died. The role of JAK2mutation in the early diagnosis of overt or silent myeloproliferative disease cannot be undermined but requires standardization.
Therefore, portal vein thrombosis is common in cirrhotic, tumor and non-tumoral, non-cirrhotic extraportal vein obstruction. EHPVO is a benign disease whereas cirrhotic and tumoral-related portal vein obstruction has a grim prognosis. Any patient with portal vein obstruction, in whom secondary cause is not known, should have hypercoagulable work up done to find out a treatable cause. Furthermore, as a primary prevention antenatal care has to be more meticulously planned and carried out.
Dr. Pankaj Jain (doing a fellowship in gastroenterology) and Dr. Sandeep Nijhawan (Professor of Gastroenterology) are working in the Department of Gastroenterology at Sawai Man Singh College and Hospital, Jaipur.
The experts opined that this research presents a large series of patients with portal vein thrombosis which they believed will be useful to the practitioners.
World Journal of Gastroenterology
Factor V Leiden mutation was present in 2% of cases and is uncommon in India. Umbilical sepsis in childhood or catheterization of umbilical veins in the neonatal period may be responsible for extrahepatic portal vein obstruction in the developing countries.
Extrahepatic portal vein obstruction (EHPVO) patients were young and commonly presented with features of hematemesis, hypersplenism, pain abdomen and abdominal distension. Ten patients had acute PVT and two had presentation as acute Budd-Chiari syndrome. Cirrhosis and tumor-related portal vein thrombosis presented with abdominal distension, abdominal pain and jaundice. On follow-up of a mean period of 7 months (range 1-24 months), 48% patients had died. The role of JAK2mutation in the early diagnosis of overt or silent myeloproliferative disease cannot be undermined but requires standardization.
Therefore, portal vein thrombosis is common in cirrhotic, tumor and non-tumoral, non-cirrhotic extraportal vein obstruction. EHPVO is a benign disease whereas cirrhotic and tumoral-related portal vein obstruction has a grim prognosis. Any patient with portal vein obstruction, in whom secondary cause is not known, should have hypercoagulable work up done to find out a treatable cause. Furthermore, as a primary prevention antenatal care has to be more meticulously planned and carried out.
Dr. Pankaj Jain (doing a fellowship in gastroenterology) and Dr. Sandeep Nijhawan (Professor of Gastroenterology) are working in the Department of Gastroenterology at Sawai Man Singh College and Hospital, Jaipur.
The experts opined that this research presents a large series of patients with portal vein thrombosis which they believed will be useful to the practitioners.
World Journal of Gastroenterology
Future for radioembolisation in patients with advanced hepatocellular carcinoma
Copenhagen, Denmark, Friday 24 April: Radioembolisation with Yttrium-90 (Y-90) glass microspheres is a safe and effective treatment for patients with advanced HCC ± portal vein thrombosis, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark.
New Jefferson Trial to Test Radiation-Emitting Beads Against Advanced Liver Cancer
Liver cancer specialists at Jefferson's Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new treatment for liver cancer. The therapy entails injecting tiny beads that emit small amounts of radiation into the liver's main artery while also blocking the blood supply feeding the cancer's growth.
Vascular and biliary complications after liver transplant can be reliably diagnosed when using CE-US
Contrast-enhanced ultrasound (CE-US) after a liver transplant is highly accurate in showing vascular as well as biliary complications, according to a recent study.
More Portal Vein Thrombosis Current Events and Portal Vein Thrombosis News Articles
 |
Portal Hypertension: Pathobiology, Evaluation, and Treatment (Clinical Gastroenterology) by Arun J. Sanyal (Editor), Vijay H. Shah (Editor) A cutting-edge review of the latest findings on key scientific topics and the best strategies for evaluation and management of portal hypertension in the clinic. Writing in an easy-to-read style, the authors review its pathobiology, the progress being made in its experimental understanding, the methodologies to assess it in humans, the treatment of its complications (esophageal varices, ascites, and hepatorenal syndrome), and its treatment in special circumstances (during pregnancy, in children, or when the portal vein is blocked). They also provide in-depth coverage of the pros and cons of the various therapeutic choices available to the clinician managing patients with complicated portal hypertension. |
|
Portal vein thrombosis: Imaging features and associated etiologies (Current problems in diagnostic radiology) by Patricia L Abbitt (Author) | |
|
Vascular and Thrombotic Diseases of the Liver (Clinical Gastroenterology) by Stephen H. Caldwell (Editor), Mark Thursz (Editor) Vascular and thrombotic diseases of the liver constitute a common set of problems that cross many sub-specialty fields and require the cooperation of multiple disciplines for optimal patient care. Vascular and Thrombotic Diseases of the Liver provides a much needed single source of information to help clinicians in caring for patients with these syndromes. All chapters are written by specialists instrumental to bringing recent change to the field in just the past few years. This multidisciplinary work provides quidelines for improved patient care by bringing controversial areas into sharper focus and by translating recent advances into practical clinical applications. It covers distinct syndromes and conditions that may have bearing on other primary diseases. Vascular... |
| © 2009 BrightSurf.com |